Two IgM monoclonal antibodies, MB32 and MB34 specific for meningococcal polysaccharide group B have been raised. Both were detectable by radioimmunoassay and agglutination, but only MB34 was effective in counter immunoelectrophoresis and complement fixation. MB34 was also far more potent than MB32 when tested for passive protection of mice infected with either Neisseria meningitidis group B or Escherichia coli K 1. These data demonstrate that group B-specific antibodies do play a protective role in mice infected with these bacteria.
this way, containing about 10' organisms ml-l, were maintained at -20 "C ; under these conditions they were found to remain stable for at least 6 months.
Preparation of meningococcalpolysaccharide group B . MPS(B) was prepared from strain CN7783 according to the procedure described by Gotschlich et al. (1972) . Chemical analysis indicated 1.3% protein and 043% nucleic acid contamination. Lipolysaccharide was estimated to be less than 0.25%. Identification was confirmed by chemical analysis of N-acetylneuraminic acid, sensitivity to neuraminidase and nuclear magnetic resonance. Immunological reactivity was estimated by counter immunoelectrophoresis with rabbit anti-B serum (Wellcome Diagnostics, Dartford) . The content of MPS(B) in the sample was estimated to be at least 95%.
Immunization procedure for obtaining monoclonal antibodies. Female CBAT6T6 mice, 8 weeks old, were given 0.7 mg Corynebucrerium paruum (Coparvax, Wellcome) on day 0 for non-specific stimulation of the immune response and splenomegaly (Adlam & Scott, 1972) . This was followed by lo8 N. meningitidis B (CN7783) given intravenously on days 4 and 11. Spleens from mice having the highest anti-B titre by solid-phase radioimmunoassay were pooled and used for fusion.
The procedure used for fusion followed the general method of (Kohler & Milstein, 1975 ) using a procedure described previously (Coates et al., 1981) . Supernatants of primary wells were screened for specific (anti-B) antibodies by solid-phase radioimmunoassay, positive wells were cloned by limiting dilution and finally grown as ascitic tumours in BALB/c x CBAT6 F1 hybrid mice primed 3 d earlier with 0.5 ml pristane (Aldrich). Ascitic supernatants were pooled and tested for activity either directly or after precipitation of the immunoglobulin at 18% (w/v) Na2S04, followed by dialysis and freeze drying. MB32 and MB34 were both IgM antibodies.
Immunological assays. Solid-phase radioimmunoassay was performed on round bottomed soft titration plates (Dynatech) pretreated with lOOpg poly-L-lysine ml-l (Sigma, mol. wt 50000) for 1 h followed by 1Opg polysaccharide ml-l and blocked with 3% (w/v) bovine serum albumin (BSA). The sera were diluted in 3% BSA (twofold dilutions), plates were incubated with 251-labelled, immunopurified rabbit anti-mouse immunoglobulin (1-3 x lo4 c.p.m. per well; 7-8 x lo6 c.p.m. pg-I) and counted. Plates were washed five times with PBS after every incubation. Antisera were diluted in 3% BSAIPBS.
Counter immunoelectrophoresis was performed as described previously (Lifely er al., 1981) using a range of antigen concentrations from 0.1 to 100 pg ml-l.
Complement fixation was done in microtitre plates (Linbro, flat bottomed microelisa). Serial twofold dilutions of monoclonal antibody (25 pl) were mixed with a range of 0-1 to 100 pg antigen ml-l (25 pl) followed by 1.8 haemolytic units of baby rabbit serum as a source of complement (50 pl). After incubation for 1 h at 37 "C, a 2% (v/v) suspension of (50 p1) sheep red blood cells previously sensitized with rabbit anti-sheep red blood cell haemolysin (Wellcome) was added and reactions were incubated for a further 2 h. Plates were centrifuged at 300 g for 15 min at an angle of 30" and haemolysis read at 405 nm in a Titertek Multiskan.
Bacterial agglutination was performed on a slide with formalin-fixed and washed bacteria (2 x 1Olo ml-l). Mouse protection model. The method used was similar to the procedures described by Calver et al., (1976) , Holbein (1980) and Holbein et al. (1979) . CBATh female mice (8 weeks old) were injected intraperitoneally with 10 mg iron dextran (Imferon, Fisons) followed within 30 min by an intraperitoneal injection of 32 LD,, of N . meningitidis suspended in PBS. Mortality was recorded for a 3 d period. The LD,, for the different strains used were as follows: CN7619, 260 c.f.u.; CN7620, 380 c.f.u.; CN7038, 7.8 x lo4 c.f.u.; CN6158, 5 c.f.u.
RESULTS
Two IgM monoclonal antibodies (MB32 and MB34) with specificity for meningococcal polysaccharide B were used in these studies. Their potency by solid-phase radioimmunoassay is illustrated in Fig. 1 . The linear segment of the curve was used to obtain the titre for each monoclonal antibody by extrapolating to zero binding, and gave values of 250 and 100ng immunoglobulin ml-l for MB32 and MB34, respectively. These titres are considerably lower than those obtained for other monoclonal antibodies specific for A and C meningococcal polysaccharides (data not shown). It is not clear whether this reflects differences in the assay system, poor avidity of anti-B monoclonals or other factors. Both monoclonals gave negative results when tested with meningococcal polysaccharides groups A and C, BSA and poly-L-lysine which served as controls for specificity.
Other immunological assays performed with MB32 and MB34 are listed in Table 1 . MB34 gave positive results in all the assays, counter immunoelectrophoresis was positive with MPS(B) but was negative with other meningococcal polysaccharides (A and C) and after treatment of MPS(B) with neuraminidase. MB32 reacted weakly in agglutination tests, was nonprecipitating by counter immunoelectrophoresis and did not fix complement. The protective capacity of MB32 and MB34 was assayed in a mouse test (Fig. 2) . This experiment indicated a clear passive protection bestowed by both MB32 and MB34 monoclonal antibodies, as seen in Fig. 2 . From these results it was clear that the minimally protective dose of MB34 demonstrable when mice were challenged with 32 LD50 of strain CN7619 was between 1 to 2 x mg per mouse. In contrast, MB32 monoclonal antibody, although it was also an IgM antibody was about 500 times less potent and no further protection studies done with it are reported here. The protective effect was also demonstrable when MB34 monoclonal antibody was given 4 h after (Table 2) or 24 h before challenge (Table 3) . In both cases, however, the protective capacity was clearly less than when antibody was given within 1 h of challenge. Since E. coli K1 polysaccharide antigen is very similar, if not identical, to MPS(B) (Bhattacharjee et al., 1975) , the capacity of MB34 to protect mice from lethal challenge with this organism was also explored (Table 4) . Although these experiments showed only partial protection by MB34 monoclonal antibody, the results however are consistent with a concept of cross-protection between N . meningitidis B and E. coli K 1. The observed difference in susceptibility is probably due to the large difference in virulence between the challenge organisms. The LD,, for E. coli K1 was found to be less than 5 c.f.u. mouse, i.e. 100 times more virulent than strain N . meningitidis CN7619 (group B). To verify the specificity MB34 was also tested in mice subsequently challenged with 32 LD,, of a group C strain (CN7038) without any positive effect. Conversely, mice challenged with group B (CN7619) strain were not protected either by normal mouse serum, or unrelated monoclonal antibodies. These results are not shown.
C . M O R E N O AND O T H E R S
Dose of antibody (mg per mouse) * Significantly different from the control, with P < 0.01.
DISCUSSION
The data present demonstrate the protective role of anti-group B meningococcal antibodies in mice. Some protection was obtained against E. coli K l ; this is in agreement with previous observations that passive antibody can protect rats injected with E. coli K1 (Bortolussi & Ferrieri, 1980) and confirms the specificity of the effect. The difference in protective capacity obtained with monoclonal antibody MB34 when tested with N . meningitidis CN7619 and E. coli K1 (CN6158) probably reflects the 100-fold difference in virulence observed for these strains, although other explanations are possible. MB34 is an IgM, complement-fixing antibody, and the complement dependence of protection against N . meningitidis (Nicholson & Lepow, 1979 ) and E. coli K1 (Stevens et al., 1978) has been reported although it has not established unequivocally whether protection is due to bactericidal activity, to C3b-dependent opsonization or both. A relationship between protection against E. coli K 1 and complement activity restricted to the classical pathway has been established (Stevens et a/., 1980) , but this is not necessarily the case for N . meningitidis.
Poor protection was observed with MB32 and complement fixation could not be demonstrated with this antibody. These findings tend to strengthen the association between complement fixation and protection. However, other factors could play a role : MB34 seems to have greater avidity for antigen than MB32 and rough estimates with the crude systems available to us would indicate approximately a 10-fold difference in avidity between the two. Moreover, Mandrel1 & Zollinger (1982) , have recently published a comparative study for avidity of human and mouse antibodies specific for meningococcal B and C antigens, and found the former to be low. It is difficult to interpret data of this kind; but it might very well be the case that MB32 did not protect for two reasons: lack of complement fixation and poor avidity.
The protective capacity of IgM monoclonal antibodies specific for Streptococcus pneumoniae type 3 and phosphorylcholine b) has been established. According to these reports, as little as 20p.g antibody (or possibly less) confers complete protection on CD mice. This compares well with the protection obtained with MB34 for N . meningitidis, as seen in Fig. 2 . Here, complete protection was obtained with 1 pg antibody, and a minimally protective dose can be put as low as 10 ng antibody per mouse. In terms of antibody molecules these data correspond to about 0-5 x 106 molecules per bacterium, a very large quantity by comparison with IgM anti-Salmonella adelaida antibody where only eight molecules per bacterium promoted phagocytosis in vivo (Rowley & Turner, 1966) . However in these experiments the bacteria and antibodies were premixed before injection, thus maximizing the efficiency of the antibody.
Although a simpler murine model based on mortality has been published (Huet & Suire, 198 1 ) , N . meningitidis is considered as poorly pathogenic for laboratory animals (Goldschneider et al., 1969) unless it is treated with mucin or administered along with iron (Holbein et al., 1979; Jones et al., 1980) which has been described as essential for bacterial multiplication in vivo (Holbein, 1980) . The fact that iron-promoted infection by N . meningitidis can be controlled with anti-B antibodies suggests that such a model could be used to study not only passive protection but also active immunity in vaccinated mice and can be considered as a useful complement to the mouse bacteraemia model as described by Craven & Frasch (1979) .
The central issue in this communication is the fact that IgM antibodies specific for polysaccharide B are sufficient to confer protection. A similar protective role of murine IgG, specific for phosphorylcholine and anti-SIII pneumococcal polysaccharide has been reported recently (Briles et al., 1981a) . We now intend to clarify whether B-monoclonal antibodies belonging to other classes and subclasses are also effective. antigens of Neisseria meningitidis serogroups B and C
